Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

American Heart Association meeting

- PMLiVE

MS and cholesterol drugs picked for new UK rapid uptake push

Accelerated Access Collaborative aims to break down barriers to faster uptake

Sanofi reception

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline

Dieter Weinand to be based in key US market

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Regeneron and Teva close gap on rivals with NGF pain drug

Fasinumab was associated with less pain and improved functional ability compared to placebo

Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

- PMLiVE

Ashfield and Sanofi scoop ICE award

Company wins the Most Effective Agency Collaboration Award for the second year running

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte

Alexander Davies considers the remarkable story of how one company broke with pharma convention to speak out on social media

Sanofi reception

Sanofi poaches Peugeot’s finance head

Jean-Baptiste Chasseloup de Chatillon joins the French drugmaker as chief financial officer

- PMLiVE

Evotec says Sanofi deal makes it anti-infectives powerhouse

Aims to inject biotech nimbleness into anti-infectives portfolio

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links